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Abstract: Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may offer a safer   alternative 
to their oral counterparts for the management of osteoarthritis. Diclofenac sodium topical solu-
tion with dimethyl sulfoxide (TDiclo) was evaluated in five randomized, controlled trials and 
is indicated for treatment of the signs and symptoms associated with osteoarthritis of the knee. 
Three studies showed that TDiclo is superior to placebo and vehicle control with respect to pain, 
physical function, and perception of osteoarthritis symptoms. Two studies showed that benefits 
are similar to those of oral diclofenac, with one study demonstrating statistical equivalence. The 
most common adverse event associated with TDiclo in these studies was dry skin. Incidences of 
gastrointestinal adverse events and abnormal levels of liver enzymes were lower with TDiclo 
compared with oral diclofenac in active-controlled studies. Based on these studies, TDiclo rep-
resents a practical, evidence-based option for the management of osteoarthritis of the knee.
Keywords: osteoarthritis, nonsteroidal anti-inflammatory drugs, diclofenac, topical 
analgesic
Introduction
Osteoarthritis is the most common form of arthritic disease. It is estimated that 
27 million US adults suffer from osteoarthritis, more than nine million of whom have 
symptomatic osteoarthritis of the knee.1 The prevalence of osteoarthritis is expected 
to rise as the population ages. Osteoarthritis has a high economic burden, with costs 
attributable to treatment and the effects of disability and comorbidity, and indirect 
costs, such as loss of earnings.2
Because there are currently no disease-modifying therapies for osteoarthritis, 
  modern management aims to relieve pain and improve function and health-related 
  quality of life.3–8 Pharmacological management of osteoarthritis usually begins 
with acetaminophen and progresses to traditional nonselective nonsteroidal anti-
  inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) selective NSAIDs. 
Most patients with osteoarthritis are likely to receive oral traditional NSAIDs or 
COX-2 inhibitors; however, the associated gastrointestinal, renal, and cardiovascular 
adverse effects of these agents can potentially limit long-term use.9–15 Topical formula-
tions of NSAIDs, recently approved by the US Food and Drug Administration (FDA) 
for the treatment of osteoarthritis, have the potential to offer a safe alternative to oral 
NSAIDs due to decreased systemic exposure to the active molecule.16Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Several international and national guidelines for the 
  management of osteoarthritis are available,3–8 all of which 
recommend a similar, multifaceted approach toward treat-
ment for individual patients that involves lifestyle changes as 
well as pharmacological therapy. These guidelines primarily 
recommend acetaminophen as first-line therapy for most 
patients. However, traditional nonselective and COX-2 selec-
tive NSAIDs are a mainstay in osteoarthritis management 
due to their well established efficacy.3–8 Topical analgesics, 
including topical NSAIDs, are recommended as an alterna-
tive therapeutic option in several guidelines, particularly for 
patients who are at risk for serious gastrointestinal or cardio-
vascular adverse events, such as elderly patients.3,5,6,17
In 2008, the UK-based National Institute for Clinical 
Excellence (NICE) published guidance recommending 
that topical NSAIDs, along with acetaminophen, should 
be the first pharmacological options in the management 
of osteoarthritis pain (after nonpharmacological treatment 
alternatives). NICE prioritizes the use of topical NSAIDs 
before the addition of oral nonselective or COX-2 selective 
NSAIDS, or opioid analgesics. The use of oral nonselec-
tive or COX-2 selective NSAIDs, starting at the lowest 
effective dosage and administered with gastroprotective 
agents   regardless of the patient’s risk for gastrointestinal 
adverse events, is recommended as a second-line treatment.8 
The NICE guidelines highlight a move to consider topical 
NSAIDs as first-line therapy.
Diclofenac is one of the most frequently used NSAIDs 
in the treatment of osteoarthritis and is the active ingredient 
in each of the several topical NSAIDs approved for use in 
the US. Among the several approved topical diclofenac for-
mulations, diclofenac sodium gel 1% and diclofenac sodium 
topical solution 1.5% (TDiclo) are approved for the treatment 
of osteoarthritis.18,19 Diclofenac sodium gel is approved for 
the treatment of the pain of osteoarthritis in joints amenable 
to topical treatment, whereas TDiclo is approved for the treat-
ment of the signs and symptoms of osteoarthritis of the knee. 
The purpose of this article is to review currently available 
data for the TDiclo formulation.
Diclofenac sodium topical  
solution with DMSO
Each 1 mL of TDiclo contains 16.05 mg diclofenac sodium. 
TDiclo solution also contains 45.5% dimethyl sulfoxide 
(DMSO) vehicle, which can result in enhanced penetration 
of active drug through the skin.20 The mechanism of action 
of DMSO is complex, including denaturation of proteins and 
interaction with the polar head groups of some lipid bilayers 
to loosen the packing geometry of the skin.21,22 In addition, 
it may facilitate drug partitioning from the formulation into 
the solvent within the skin tissue.22
Efficacy studies
Five double-blind, randomized, clinical trials of   TDiclo 
have been published (Table 1).23–27 Three trials were 
  placebo-controlled and/or vehicle/active-controlled.23–25 One 
trial included a topical diclofenac arm, an oral diclofenac 
arm, a topical plus active control (oral diclofenac) arm, a 
  placebo control, and a vehicle control,26 and one trial was 
an equivalence study comparing topical diclofenac with oral 
diclofenac.27
Patient demographics
All patients included in the five studies were adults with 
primary osteoarthritis of the knee based on standard radio-
logical criteria (defined by joint space narrowing and mar-
ginal osteophytes in the medial, lateral, and patellofemoral 
compartments).28 The total number of patients in each study is 
shown in Table 1. The mean age of the included patients was 
approximately 60–65 years, and approximately 60%–70% 
in each study were female. Patients applied TDiclo around 
the affected knee at a dose of 40 drops (about 1.2 mL) four 
times daily23–26 or 50 drops (about 1.5 mL) three times daily 
in the equivalence study.27 Concomitant NSAIDs and other 
analgesics were not allowed during the studies. Use of res-
cue acetaminophen was permitted in all studies except the 
equivalence study,27 with up to four 325 mg tablets per day 
allowed in three studies,24–26 and up to two 325 mg tablets four 
times daily allowed in the other study.23 Low-dose aspirin was 
allowed for cardiovascular prophylaxis in all studies.
In three of the five studies, patients were required to 
have experienced a flare of pain after washout of previous 
therapy (Table 1). Pain flares were defined as an increase on 
the Western Ontario and McMaster Universities (WOMAC) 
Osteoarthritis Index pain subscale of $2 points and 25%, 
score of $2 (moderate) on at least one of the five questions 
of the pain subscale, and baseline total pain score $6.24 The 
WOMAC Osteoarthritis Index is a validated questionnaire 
consisting of 24 questions (five about pain, 17 about physical 
function, and two about stiffness).
Outcome measures
Efficacy variables in the studies included measures of 
pain, physical function, and patients’ perception of their 
osteoarthritis symptoms and/or overall health (Table 1). 
It is important to note that this core set of outcome   measures Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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complies with the recommendations of the Outcome 
  Measures in Arthritis Clinical Trials (OMERACT) III,29 the 
Osteoarthritis Research Society International (OARSI),30 
and the Group for the Respect of Ethics and Excellence in 
Science.31 The WOMAC Osteoarthritis Index pain score, 
the WOMAC Osteoarthritis Index physical function score, 
and the Patient Global Assessment (PGA) score were 
coprimary efficacy variables in three of the five studies. 
One of the remaining studies utilized the Patient Overall 
Health Assessment (POHA) score instead of the PGA as the 
third coprimary endpoint. The PGA question asks patients 
about their osteoarthritis in the target knee during the past 
48 hours, whereas the POHA question asks patients how 
they rated their overall state of health in the past 48 hours 
in relation to their osteoarthritis knee and its treatment. The 
fifth study evaluated only the WOMAC pain score as a pri-
mary endpoint and evaluated all other scales as a part of its 
secondary endpoints (Table 1). Secondary efficacy variables 
included the WOMAC stiffness subscale and pain on walk-
ing (the first question in the WOMAC pain assessment). All 
  questions were scored on a five-point Likert scale, except in 
the equivalence study, in which questions were scored on a 
100 mm visual analog scale.
Efficacy vs DMSO vehicle or placebo
In all four placebo-controlled or vehicle-controlled studies, 
TDiclo showed statistically significant improvements vs pla-
cebo and/or vehicle in WOMAC pain score (Figure 1). Mean 
improvement in scores for TDiclo vs vehicle control in each 
of the four studies was −3.9 vs −2.5 (P = 0.023),23 −5.9 vs −4.3 
(P = 0.001),24 −5.2 vs −3.3 (P = 0.003),25 and −6.0 vs −4.7 
(P = 0.009).26 The mean percent improvement in WOMAC 
pain score from baseline to final assessment with TDiclo 
was 42.9%,23 45.7%,24 40.0%,25 and 45.5%.26 In contrast, 
the percent change with vehicle or placebo ranged between 
26.0% and 36.4%.
Statistically significant improvements in WOMAC physi-
cal function compared with vehicle and/or placebo were also 
shown in all four studies (Figure 2). Mean change in scores 
for TDiclo vs vehicle control in each of the four studies was 
−11.6 vs −5.7 (P = 0.002),23 −15.4 vs −10.1 (P = 0.002),24 
−13.4 vs −6.9 (P = 0.001),25 and −15.8 vs −12.1 (P = 0.026).26 
Improvements with TDiclo corresponded to a percent 
improvement from baseline to final assessment of 39.3%,23 
36.7%,24 32.8%,25 and 37.9%,26 compared with 17.1%–29.6% 
for vehicle or placebo.
Patients who used TDiclo also reported better overall 
health status as assessed by the POHA or PGA, with a sta-
tistically significant difference vs vehicle and/or placebo in 
all studies (Table 2).23–26 Mean change from baseline to final 
assessment in PGA for TDiclo vs vehicle control in each 
of the three studies assessing PGA as a primary outcome 
was −1.3 vs −0.9 (P = 0.003),24 −1.3 vs −0.7 (P = 0.0001),25 
and −1.36 vs −1.07 (P = 0.018).26 For TDiclo, the percent 
improvement was 42.2%,24 41.9%,25 and 43.6%,26 compared 
with 21.9%–34.2% for vehicle or placebo. Bookman et al 
assessed PGA as a secondary variable and showed similar 
results.23 After 4 weeks of treatment, TDiclo was associated 
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Table 2 Patient perception of osteoarthritis symptoms and overall health status as assessed by the PGA or POHA, after treatment 
with diclofenac sodium topical solution, vehicle control, or placebo
Reference Variable TDiclo Vehicle  
control
P valuea Placebo  
control
P valueb
Bookman et al23 PGA (sum of scores at  
weeks 1, 2, 3, and 4)
6.7 7.8 0.039 7.8 0.025
Roth and Shainhouse24 PGA (change from baseline) −1.3 (42.2%) −0.9 (30.4%) 0.003 – –
Baer et al25 PGA (change from baseline) −1.3 (41.9%) −0.7 (21.9%) 0.0001 – –
Simon et al26 PGA (change from baseline)
POHA (change from baseline)
−1.36 (43.6%)
−0.95 (40.6%)
−1.07 (34.2%)
−0.65 (28.3%)
0.018
0.016
−1.01 (33.2%)
−0.37 (16.7%)
0.016
,0.0001
Notes: aTDiclo vs vehicle control; bTDiclo vs placebo. PGA and POHA were assessed on a scale of 0 to 4. values shown indicate change from baseline (% improvement).
Abbreviations: OA, osteoarthritis; PGA, Patient Global Assessment; POHA, Patient Overall Health Assessment; TDiclo, diclofenac sodium topical solution.
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diclofenac sodium topical solution and oral diclofenac.
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with a significantly better mean PGA score (6.7) compared 
with vehicle control and placebo (7.8 in both groups, 
P = 0.039).23 A single study utilizing POHA showed a mean 
change from baseline to final assessment for TDiclo vs 
vehicle control of −0.95 vs −0.65 (P = 0.016).26
Greater improvements in WOMAC stiffness score with 
TDiclo vs vehicle and/or placebo were also observed; all 
improvements were statistically significant (P , 0.05) other 
than the comparison with placebo in the study by Simon 
et al.26 Statistically significant (P , 0.05) improvements 
compared with vehicle and/or placebo were also seen for 
pain on walking.23–25
Efficacy vs oral diclofenac
Two studies of TDiclo have compared efficacy of the solu-
tion vs oral diclofenac.26,27 One of the studies also included 
placebo and vehicle control arms, as described above.26 In 
the oral diclofenac arm, patients received diclofenac 100 mg 
once daily in a extended-release formulation (Novopharm 
Ltd, Stouffville, ON). The efficacy of TDiclo was equivalent 
to that of oral diclofenac, and no statistically significant dif-
ferences were observed between the two treatments in a post 
hoc analysis. The mean changes in outcomes measurement 
scores for TDiclo vs oral diclofenac were −6.0 vs −6.4 for 
WOMAC pain score, −15.1 vs −17.5 for WOMAC physical 
function score, −0.95 vs −0.88 for POHA, and −1.36 vs −1.42 
for PGA. These differences were not statistically significant. 
Percent improvements for these outcome measures with 
TDiclo ranged from 38% to 45%, and with oral diclofenac 
ranged from 39% to 48% (Figure 3). In addition to the oral 
diclofenac arm, this study also included a treatment arm in 
which patients received both oral diclofenac and the topical 
solution (Table 1). The combination did not produce greater 
improvements compared with oral diclofenac alone.
The second active comparator study was designed 
as an equivalence trial (Table 1).27 Oral diclofenac was 
  administered at a dose of 50 mg three times daily. The copri-
mary efficacy variables were WOMAC pain, WOMAC phys-
ical function, and PGA, measured on a 100 mm visual analog 
scale. To demonstrate equivalence between TDiclo and oral 
diclofenac, two-sided 95% confidence intervals (CIs) were 
calculated for the difference between treatments in the mean 
change in score for each of the coprimary efficacy   variables. Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Adverse events in studies comparing diclofenac sodium 
topical solution with oral diclofenac26,27
Adverse events  
(%)
Tugwell et al27 Simon et al26
TDiclo Oral  
diclofenac
TDiclo Oral  
diclofenac
Application site
Dry skin 27 1a 18.2 2.6
Rash 12 2a – –
Paresthesia 0.6 0.6 – –
Pruritus 6 0.6a 1.3 0.0
Urticaria 0.3 0.3 – –
vesiculobullous rash 5 0a 1.9 0.7
Contact dermatitis – – 2.6 0.7
Gastrointestinal
All Gi events 35 48a 6.5 23.8
Abdominal pain 12 22a 3.2 7.3
Constipation 8 10 – –
Diarrhea 9 17a 1.3 4.6
Dyspepsia 15 26a 2.6 4.0
Flatulence 10 17a – –
Melena 1 2 – –
Nausea 8 13a 0.0 2.0
vomiting 2 2 ND ND
Laboratory parametersb
AST 2 10a 6.9 19.6
ALT 5 17a 4.1 18.8
Hemoglobin 2 10a 2.1 5.8
Creatinine 1 3 2.8 7.2
Notes: aP , 0.05 vs TDiclo with DMSO. No statistical analysis was performed in 
Simon et al;26  bPercentage of patients changing from normal levels at baseline to 
abnormal levels during the study.
Abbreviations: Gi, gastrointestinal; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase;  DMSO,  dimethyl  sulfoxide;  TDiclo,  diclofenac  sodium  topical 
solution.
The treatments were considered equivalent if the CIs were 
in the range of −75 to 75 mm for WOMAC pain score 
(±15 mm for each of the five questions in the WOMAC pain 
subscale), −255 to 255 mm for WOMAC physical function 
score (±15 mm for each of the 17 questions in the WOMAC 
physical function subscale), and −20 to 20 mm for PGA. 
These limits were based on the minimal clinically important 
difference in osteoarthritis trials that was previously estab-
lished by a panel of expert rheumatologists.32 The primary 
analysis was performed in the per protocol population, as is 
typical for equivalence studies.
The 95% CIs for the three coprimary efficacy parameters 
were well within the predefined limits; therefore, the analysis 
demonstrated equivalence of TDiclo and oral diclofenac. The 
difference between treatments in mean change in score from 
baseline was 13.3 mm (95% CI: −8.6–35.2) for WOMAC pain 
score, 71.0 mm (95% CI: −2.4–144.5) for WOMAC physi-
cal function score, and 4.3 mm (95% CI: −1.2–9.8) for PGA. 
TDiclo treatment resulted in a 44% improvement in pain, 39% 
improvement in physical function, and 43% improvement in 
PGA (Figure 3).26,27 No statistically significant differences were 
seen between treatments in the per protocol data set. Similar 
efficacy results were seen for stiffness and pain on walking.
Safety data
Plasma levels of diclofenac
The concentration of diclofenac reached in plasma is con-
siderably lower after topical application compared with oral 
administration. In a study of a single application of 1 mL 
TDiclo to one knee in healthy volunteers, the maximum plasma 
concentration was 11.8 ± 4.2 ng/mL (standard deviation) after 
24–48 hours.33 In another single-dose study in healthy volun-
teers, the maximum plasma concentration was 8.1 ± 5.9 ng/mL 
approximately 10 hours after an application of 40 drops 
(approximately 1.2 mL) to each knee.19 Following application 
of 40 drops to each knee four times daily for 7 days in healthy 
volunteers, maximum plasma concentration at steady state was 
19.4 ± 9.3 ng/mL.19 In contrast, following administration of oral 
diclofenac 50 mg every 8 hours in a separate study, maximum 
plasma concentration at steady state was 2270 ng/mL.34
Tolerability and adverse  
events vs oral diclofenac
The incidence of adverse events occurring in the two ran-
domized, controlled studies comparing TDiclo with oral 
diclofenac is shown in Table 3.26,27 Both studies included a 
dermatological assessment of the knee to evaluate   application 
site reactions,26,27 and the equivalence study included a 
  statistical comparison of adverse event incidence between 
the study groups.27 Most adverse events occurring in patients 
treated with TDiclo were application site reactions. Dry skin 
was by far the most common, occurring in 27% of patients 
treated with TDiclo in the equivalence study27 and in 18.2% of 
patients in the other active controlled study26 (Table 3). In the 
equivalence study, a statistically significant higher incidence 
of dry skin, rash, pruritus, and vesiculobullous rash occurred 
with TDiclo compared with oral diclofenac (Table 3).27 More 
patients withdrew due to skin-related adverse events in the 
TDiclo group than in the oral diclofenac group (10% vs 0.3%, 
P , 0.0001).27 A much lower rate of study discontinuation 
due to application site reactions (3.2%) was seen in the TDi-
clo arm of the other active-controlled study.26 The dry skin 
seems to be in part related to the DMSO vehicle, because it 
was also observed in patients treated with vehicle control.23–26 
In clinical practice, emollients may be used after the topical 
solution has dried in order to alleviate skin dryness; however, 
this practice was not specifically evaluated during the course Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Figure 4 Skin irritation scores in a long-term, open-label study of diclofenac sodium 
topical solution.36
Notes: 0 = normal; 0.5 = dryness or flaking; 1 or 2 = erythema with or without 
induration; 3 or 4 = erythema with induration and vesicles or bullae.
of the study, so it is not known to what extent emollients will 
alleviate these application site reactions.
Gastrointestinal adverse events occurred more frequently 
with oral diclofenac in both active-controlled studies 
(Table 3). In the study reported by Simon et al,26 gastrointes-
tinal adverse events occurred in 23.8% of patients receiving 
oral diclofenac vs 6.5% of patients receiving TDiclo. In the 
equivalence study, gastrointestinal events occurred in 48% of 
patients receiving oral diclofenac vs 35% of patients receiving 
TDiclo (P , 0.05). Specific gastrointestinal adverse events 
for which a statistically significant difference between groups 
was shown included abdominal pain, diarrhea, dyspepsia, 
flatulence, and nausea (Table 3). There was no significant 
difference between the study groups with respect to con-
stipation, melena, and vomiting. The proportion of patients 
with a gastrointestinal adverse event classified as severe was 
greater in the oral diclofenac group (21.3%) compared with 
the TDiclo group (7.4%), and the same pattern was observed 
for abdominal pain, dyspepsia, and diarrhea.27
Significantly more patients withdrew due to   gastrointestinal 
adverse events in the oral diclofenac group than in the TDiclo-
group (16% vs 6%, respectively, P , 0.0001).   Interestingly, 
a much lower incidence of gastrointestinal adverse events 
was reported with TDiclo in the three randomized, placebo- 
and/or vehicle-controlled studies23–25 compared with the 
active-controlled studies. This is consistent with a systematic 
review of oral NSAID trials that showed a higher incidence 
of gastrointestinal adverse events in active comparator trials 
compared with placebo-controlled trials.35
In addition, laboratory parameters changed from normal to 
abnormal levels in a greater number of patients receiving oral 
diclofenac compared with TDiclo in both   active-controlled 
studies (Table 3). In the equivalence study, a statistically sig-
nificant difference between treatment groups was observed in 
elevations in aspartate aminotransferase, alanine aminotrans-
ferase, and hemoglobin levels. However, there was no differ-
ence between study groups in the incidence of hypertension 
or cardiovascular events in either study.26,27
Long-term safety
TDiclo was well tolerated in controlled clinical trials of 
6–12 weeks’ duration. However, because patients with 
osteoarthritis of the knee are likely to use topical NSAIDs 
over the course of many years, it is important to gain an 
understanding of long-term safety reflecting use in clini-
cal practice. An open-label, prospective study evaluated 
the safety of TDiclo for up to 52 weeks.36 The study was 
conducted at outpatient centers and included 793 patients 
aged 35–85 (mean 62.5) years with radiologically confirmed 
osteoarthritis of the knee. Patients applied 40 drops of   TDiclo 
to the knee four times daily. The most common adverse 
event reported was dry skin at the application site (25.3% of 
patients), followed by contact dermatitis (13.0%) and contact 
dermatitis with vesicles (9.5%). However, dermatological 
assessment of the application site showed that most patients 
had a normal skin irritation score (Figure 4).36
In this open-label, long-term study, gastrointestinal 
adverse events occurred in 12% of patients, including 
abdominal pain in 2.3%, gastroesophageal reflux in 1.6%, 
diarrhea in 1.4%, dyspepsia in 1.4%, and nausea in 1.1%. 
A total of 28 cases of hypertension were reported (3.5% of 
patients).36 However, most of these patients had hypertension 
at study enrolment; only 13 (1.6%) were considered to be true 
cases of new-onset or worsening hypertension. Other cardio-
vascular adverse events that occurred in $0.5% of patients 
were peripheral edema (1.4%), angina/chest pain (0.8%), 
palpitation (0.6%), myocardial infarction (0.5%), arrhythmia 
(0.5%), deep vein thrombosis (0.5%), and vasodilatation 
(0.5%). Prolonged exposure to TDiclo with DMSO resulted 
in few changes in hemoglobin, aspartate aminotransferase, 
alanine aminotransferase, or creatinine values. A change from 
normal to abnormal levels occurred in 3.2% of patients for 
hemoglobin, 6.4% for aspartate aminotransferase, 7.3% for 
alanine aminotransferase, and 4.2% for creatinine.36
DMSO-related adverse reactions
Preclinical studies of DMSO have resulted in rare reports 
of ocular lens abnormalities with high-dose exposure in 
nonprimate species,37 although studies in humans have found Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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no ocular toxicity even with high doses applied topically 
or directly to the eye.38–40 In the controlled trial reported by 
Simon et al,26 there was no increase in eye abnormalities in 
the TDiclo groups or the vehicle control group compared 
with placebo. In the long-term safety study, cataracts were 
reported in 18 patients (3% of those who received an ocular 
examination); seven patients developed a new cataract, 
whereas progression of an existing cataract was reported 
in 11 patients.36 These cataract event rates appeared to be 
somewhat lower than seen in natural history studies.41–45 
Another adverse reaction that may be attributed to DMSO is 
a garlic taste or odor, due to exhalation of dimethyl sulfide, 
a metabolite of DMSO. However, a low incidence of taste 
perversion (0.6%–3.7%) and halitosis (0%–5%) was reported 
in all studies reported here.23–27,36
Comments and conclusion
Oral nonselective NSAIDs have shown to be effective and 
are widely used in the treatment of osteoarthritis, but these 
agents are associated with a risk of serious gastrointestinal 
and cardiovascular adverse events.9 These events, which 
can be fatal and may occur without warning, are the basis of 
the boxed warning in the prescribing information required 
by the FDA and the required risk evaluation and mitigation 
strategy program, which includes a medication guide.9,46 
When determining a pain management plan in patients with 
osteoarthritis, minimizing risk is a priority.9
TDiclo may provide analgesia similar to oral NSAIDs 
with significantly lower dosage and systemic absorption 
of the active drug. Lower systemic concentrations may 
therefore result in less risk of systemic adverse events, 
including the gastrointestinal events discussed above. 
At this time, the prescribing information for topical 
NSAIDs also includes the classwide boxed warning regard-
ing gastrointestinal and cardiovascular events.18,19 Based 
on the summary of data reported here, by adopting topi-
cal NSAID treatment as the first method of intervention 
for osteoarthritis, healthcare professionals may be able to 
decrease the risk of adverse events without compromising 
the efficacy of treatment.
TDiclo demonstrated efficacy in osteoarthritis of the knee 
similar to oral diclofenac in large, well-designed, randomized, 
controlled trials. Dry skin was the most frequent adverse 
event observed, but systemic NSAID class-related adverse 
events and laboratory abnormalities were considerably less 
with TDiclo compared with oral diclofenac. Topical NSAIDs 
have not been included in some clinical guideline recommen-
dations because of a lack of data concerning overall efficacy. 
As more data about topical NSAIDs are published, health 
organizations will have new opportunities to evaluate these 
data as they update their existing recommendations. Clinical 
studies to date show that TDiclo represents a practical and 
evidence-based option for the management of osteoarthritis 
of the knee.
Disclosure
PF is an employee of Covidien, the distributor of Pennsaid® 
(diclofenac sodium topical solution 1.5% w/w) in the US. 
SR serves as a consultant and speaker for Covidien, and is a 
current stakeholder in Transdel Pharmaceuticals.
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